Table 1.

Actionable oncogene alterations in NSCLC and corresponding targeted therapies.

Gene Alteration	Freq.	Targeted Therapy	Ref.
EGFR activating mutations	15–50%	Erlotinib	[10]
		Gefitinib	[11]
		Afatinib	[12]
		Dacominib	[13]
		Icotinib	[14]
		Osimertinib	[15]
		Mobocertinib	[16]
		Poziotinib	[17]
ALK rearrangement	4%	Crizotinib	[18]
		Ceritinib	[19]
		Alectinib	[20]
		Brigatinib	[21]
		Lorlatinib	[22]
MET exon 14 skipping mutations	4%	Crizotinib	[23,24]
		Cabozantinib	[25]
		Capmatinib	[26]
		Tepotinib	[27]
		Savolitinib	[28]
BRAF mutations	3%	Vemurafenib	[29]
		Dabrafenib	[30]
		Dabrafenib + Trametinib	[31]
HER2 mutations	3%	Trastuzumab	[32]
		Neratinib	[33,34]
		Afatinib	[35]
		Lapatinib	[36]
ROS1 rearrangement	1–2%	Crizotinib	[37]
		Ceritinib	[38]
		Lorlatinib	[39,40]
		Entrectinib	[41]
RET rearrangement	1–2%	Vandetanib	[42]
		Cabozantinib	[43,44]
		Pralsetinib	[45]
		Selpercatinib	[46]
NTRK fusion	<1%	Entrectinib	[47,48]
		Larotrectinib	[48]
		Selitrectinib	[49]
Kras G12C mutation	13%	Sotorasib	[50]
		Adagrasib	[51]
		Adagrasib

Freq.: percentage among non-squamous NSCLC [8,9,52].